"GLP-1 medications have been central to Hims' meteoric rise - and its recent near-collapse. Compounded versions of semaglutide and tirzepatide attracted hundreds of thousands of new subscribers. Last year, Hims boasted roughly 418,000 weight-loss customers. These low-cost offerings (often around $199 to $300 per month) not only delivered direct sales but acted as a powerful funnel: once patients signed up for GLP-1s, many stayed for Hims' core offerings - hair-loss treatments, erectile-dysfunction meds, skincare, and mental-health services."
"Then came the surprise truce announced last Friday: Novo dropped the lawsuit (while reserving the right to refile), and Hims agreed to sell branded Wegovy and Ozempic - including the new oral Wegovy pill - directly on its platform. Hims will also stop advertising compounded versions except on a limited scale and transition most patients to the real thing. The market roared back. Since the deal, HIMS stock has soared 64%, capped by a stunning 40% one-day gain."
"The compounded drugs carried risks, however. Regulatory scrutiny highlighted safety concerns around unapproved formulations, inconsistent dosing, and aggressive advertising. The FDA's warnings last month and DOJ referrals created a cloud of legal and reputational danger."
Hims & Hers faced severe challenges in 2024 after the FDA cracked down on compounded GLP-1 drugs, resulting in a 75% stock decline. The company faced warning letters, potential criminal investigations, and a patent-infringement lawsuit from Novo Nordisk. A settlement announced last Friday reversed this trajectory: Novo dropped its lawsuit, and Hims agreed to sell branded Wegovy and Ozempic directly through its platform while limiting compounded drug advertising. This pivot represents a strategic shift from low-cost compounded medications to premium branded alternatives. GLP-1 drugs had been central to Hims' growth, attracting hundreds of thousands of weight-loss customers and serving as a funnel for cross-selling other services like hair-loss treatments and mental-health offerings. The settlement addresses regulatory concerns about safety and marketing practices while positioning Hims to capitalize on the branded GLP-1 market.
#glp-1-medications #telehealth-regulation #patent-settlement #pharmaceutical-marketing #stock-recovery
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]